1x 베팅 주소 Pharmaceutical Co., Ltd.
1x 베팅 주소 Holdings Co., Ltd.

Tokyo, Japan, June 13, 2011 -- 1x 베팅 주소 Pharmaceutical Co., Ltd. today announced the initiation of the phase I clinical trial of OCV-105 for pancreatic cancer in Japan. OCV-105 is a potential therapeutic cancer vaccine which has been co-developed by OncoTherapy Science, Inc. and 1x 베팅 주소 Pharmaceutical.

OCV-105 is a therapeutic cancer vaccine targeting the tumor specific antigen which is highly expressed with high frequency 1x 베팅 주소 pancreatic cancer. It is expected that OCV-105 suppresses the growth and progress of pancreatic cancer by the induction and activation of cytotoxic T-cells which directly damage pancreatic cancer cells.
1x 베팅 주소 phase I clinical trial will evaluate 1x 베팅 주소 safety of OCV-105 in patients with pancreatic cancer refractory to or intolerance to 1x 베팅 주소 standard 1x 베팅 주소rapy.

Based on its corporate philosophy of '1x 베팅 주소-people creating new products for better health worldwide,' 1x 베팅 주소 Pharmaceutical is dedicated to contributing to the health of people around the world.